

## **Boston Scientific Announces Public Offering of Senior Notes**

(November 15, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today the launch of a public offering of two series of its senior notes under the Company's existing shelf registration statement. The two series of senior notes will have varied maturities and a combined aggregate principal amount of \$500 million.

Boston Scientific plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes. The joint bookrunners for the offering are Merrill Lynch & Co., UBS Investment Bank and Wachovia Capital Markets, LLC.

Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made by means of a prospectus and related preliminary prospectus supplement only, copies of which or information concerning this offering may be obtained by contacting Merrill Lynch & Co., Attn: Prospectus Department, 4 World Financial Center, New York, NY 10080, (212) 449-1000; UBS Investment Bank, Attn: Tony Colorafi, 677 Washington Blvd., Stamford, CT 06901, (203) 719-1088; or Wachovia Capital Markets, LLC, Attn: Christopher Burren, 301 South College Street, Charlotte, NC 28288, (704) 383-7727.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward looking statements and may be adversely affected by, among other things, risks associated with capital markets, new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.

---

<https://news.bostonscientific.com/news-releases?item=58807>